EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Case Report: Complete metabolic response to alectinib in a TNS1-ALK-rearranged uterine inflammatory myofibroblastic tumor, with stereotactic body radiotherapy for oligoprogression

Hakan Özçelik, Ahmet Levent Güner, Işık İkbal Barış, Burçin Çakan Demirel, Ahmet Bilici

Frontiers in Pharmacology · 2026-11-12 · 17

DOI: 10.3389/fphar.2026.2003728 ↗
AbstractBibliografische Angaben

Abstract

Inflammatory myofibroblastic tumors of the uterus harboring a TNS1-ALK fusion are rare, and their response to the anaplastic lymphoma kinase ( ALK ) inhibitor alectinib, including the management of oligoprogression with stereotactic body radiotherapy, is poorly documented. Inflammatory myofibroblastic tumors (IMTs) are mesenchymal tumors that, although generally regarded as rare and low-grade neoplasms, have the potential for local recurrence and, rarely, distant metastasis. Anaplastic lymphoma kinase ( ALK ) gene rearrangements are detected in approximately half of IMTs, representing an important biomarker for targeted therapies. Here we present a 53-year-old woman diagnosed with an inflammatory myofibroblastic tumor of uterine origin who developed metastatic recurrence after surgery and, following the detection of ALK fusion positivity ( TNS1-ALK ), achieved a complete metabolic response with alectinib therapy. A CHEK2 mutation was also identified in the patient, who was evaluated for hereditary cancer predisposition. A rapid response was achieved with alectinib in both the pulmonary metastases and the vaginal recurrence site. After approximately 12 months of alectinib therapy, limited (oligoprogressive) disease developed in the lung; stereotactic body radiotherapy was applied to the pulmonary nodules while systemic alectinib therapy was continued. This case highlights the efficacy of ALK inhibitors in the treatment of IMT and the critical importance of identifying molecular targets in rare tumors.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →